Celldex Therapeutics diskutieren
Celldex Therapeutics
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
?
2,37 %
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $25.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $68.00 price target on the stock, up from $58.00.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) was upgraded by Wolfe Research from "peer perform" to "outperform". They now have a $44.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target raised by Barclays PLC from $45.00 to $48.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target raised by Wells Fargo & Company from $38.00 to $54.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target raised by UBS Group AG from $38.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $42.00 price target on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target raised by Guggenheim from $90.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Canaccord Genuity Group Inc. from $62.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Cantor Fitzgerald from $67.00 to $61.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Morgan Stanley from $44.00 to $40.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Wells Fargo & Company from $54.00 to $48.00. They now have an "overweight" rating on the stock.
Ratings data for CLDX provided by MarketBeat
Neueste Beiträge
B__Riley_Financial__ in Varonis Systems Inc. diskutieren